Resources
108 Results (showing 51 - 60)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/21/2021 (updated 4/2/2024)
RCORP-TA and federal experts provided updates on the process for obtaining and using a waiver to prescribe buprenorphine for the treatment of opioid use disorder with ample time for questions and answers from participants.
Presenter(s): Dr. Melinda Campopiano & Monica Rousseau, DrPH
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.
Posted 7/7/2021 (updated 4/2/2024)
This presentation highlighted the intersection of discrimination, women, substance use and reproductive rights from historical and current perspectives. It then provided methods and techniques for eliminating stigma and discrimination on a provider-patient level and provide an opportunity for the audience to practice compassionate care.
Posted 6/30/2021 (updated 4/2/2024)
In this context, the overarching aim of this document is to inform and encourage governments, policy–makers, and other partners to take the necessary actions to implement evidence-based prevention strategies and treatment services for substance use disorders in order to provide everybody, girls as well as boys, and women as well as men, with the skills and opportunities to prevent the initiation of unhealthy behaviours and, in case of individuals who use drugs and suffer from drug use disorders, with the optimal support for improving their life circumstances.
Posted 6/30/2021 (updated 4/2/2024)
This guidance publication is intended to support the efforts of states, tribes, and local communities in addressing the needs of pregnant women with opioid use disorders and their infants and families. National data show that from 2000 to 2009 the use of opioids during pregnancy increased from 1.19 to 5.63 per 1,000 hospital births (Patrick, Schumacher, Benneyworth, Krans, McAllister, & Davis, 2012). Because of the high rate of opioid use and misuse among all women, including pregnant women, medical, social service, and judicial agencies are having to confront this concern more often and, in some communities, at alarming rates.
This guidance document provides background information on the treatment of pregnant women with opioid use disorders, summarizes key aspects of guidelines that have been adopted by professional organizations across many of the disciplines, presents a comprehensive framework to organize these efforts in communities, and provides a collaborative practice guide for community planning to improve outcomes for these families. A set of appendices provides details on implementing the recommendations in the guide as well as a summary of lessons from one community’s experience over the past decade.
Posted 6/17/2021 (updated 4/2/2024)
Telemedicine is increasingly being used to treat patients with opioid use disorder (OUD). It has particular value in rural areas of the United States impacted by the opioid crisis as these areas have a shortage of trained addiction medicine providers. Patient satisfaction significantly impacts positive clinical outcomes in OUD treatment and thus is of great clinical interest.
Posted 6/17/2021 (updated 4/2/2024)
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.
Objective:To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence
Posted 10/19/2020 (updated 3/29/2024)
The Providers Clinical Support System (PCSS) Mentoring Program support is recommended for clinicians who are contemplating or have recently begun prescribing MOUD and would like additional support. PCSS offers three tiers of service at no cost to the recipient: (1) a discussion forum, (2) the ability to submit a clinical question through the PCSS website, and (3) one-on-one mentoring.
Posted 10/12/2020 (updated 3/29/2024)
This update of the National Institute on Drug Abuse’s Principles of Drug Addiction Treatment is intended to address addiction to a wide variety of drugs, including nicotine, alcohol, and illicit and prescription drugs. It is designed to serve as a resource for healthcare providers, family members, and other stakeholders trying to address the myriad problems faced by patients in need of treatment for drug abuse or addiction.